Collaboration, License and Option Agreement Sample Contracts
ContractCollaboration, License and Option Agreement • May 5th, 2020 • New York
EX-10.1 2 xlrn-20180630xexhibit101.htm EXHIBIT 10.1 Exhibit 10.1 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION, LICENSE AND OPTION AGREEMENT by and between ACCELERON PHARMA, INC. and CELGENE CORPORATION August 2, 2011 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. TABLE OF CONTENTS
COLLABORATION, LICENSE AND OPTION AGREEMENT by and between ACCELERON PHARMA, INC. and CELGENE CORPORATIONCollaboration, License and Option Agreement • August 4th, 2016 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • New York
This Collaboration, License and Option Agreement (this “Agreement”) dated the 20th day of February, 2008 (the “Execution Date”) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 149 Sidney Street, Cambridge, MA 02139 (“Acceleron”), and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (“Celgene”). Acceleron and Celgene may each be referred to herein individually as a “Party” and collectively as the “Parties.”
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION, LICENSE...Collaboration, License and Option Agreement • March 16th, 2021 • Curis Inc • Biological products, (no disgnostic substances) • New York
This Collaboration, License and Option Agreement (the “Agreement”) is entered into as of January 18, 2015 (the “Effective Date”), by and between Aurigene Discovery Technologies Limited, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (“Aurigene”), and Curis, Inc., a corporation organized under the laws of Delaware, USA, having an address of 4 Maguire Road, Lexington, Massachusetts 02421-3112, USA (“Curis”).
FIRST AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENTCollaboration, License and Option Agreement • March 16th, 2021 • Curis Inc • Biological products, (no disgnostic substances)
This First Amendment to Collaboration, License and Option Agreement (the “Amendment”) is entered into as of September 7, 2016 (the “Amendment Date”), by and between Aurigene Discovery Technologies Limited, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (“Aurigene”), and Curis, Inc., a corporation organized under the laws of Delaware, USA, having an address of 4 Maguire Road, Lexington, Massachusetts 02421-3112, USA (“Curis”).
COLLABORATION, LICENSE AND OPTION AGREEMENT By and Between Cue Biopharma, Inc. and LG Chem, Ltd. Dated as of November 6, 2018Collaboration, License and Option Agreement • December 26th, 2018 • Cue Biopharma, Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION, LICENSE AND OPTION AGREEMENT (this “Agreement”) is entered into as of November 6, 2018 (the “Effective Date”), by and between CUE BIOPHARMA, INC., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG CHEM LTD., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”. Contemporaneously, the Parties are entering into a Stock Purchase Agreement dated the Effective Date for LGC’s purchase of Cue’s publicly traded common stock and an amendment of the Einstein License Agreement (as defined below).
COLLABORATION, LICENSE AND OPTION AGREEMENTCollaboration, License and Option Agreement • March 20th, 2024 • BioNTech SE • Biological products, (no disgnostic substances) • England and Wales
This COLLABORATION, LICENSE AND OPTION AGREEMENT (this "Agreement") is entered into this 26th day of October, 2023 (the "Execution Date"), by and between
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Ninth Amendment TO...Collaboration, License and Option Agreement • March 31st, 2025 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Ninth Amendment to the Collaboration, License and Option Agreement (the “Ninth Amendment”) is entered into as of the last signature set forth below (the “Ninth Amendment Effective Date”), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 40 Guest Street, Boston, MA 02135 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
THIRD Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Third Amendment to the Collaboration, License and Option Agreement (the “Third Amendment”) is entered into as of October 29, 2019 (the “Third Amendment Effective Date”) by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Collaboration, License...Collaboration, License and Option Agreement • May 8th, 2025 • Xilio Therapeutics, Inc. • Pharmaceutical preparations • New York
This Collaboration, License and Option Agreement (this “Agreement”) is made and entered into as of February 10, 2025 (the “Effective Date”) by and between Xilio Development, Inc., a Delaware corporation (“Xilio”), on the one hand and AbbVie Group Holdings Limited, a corporation organized under the laws of Bermuda (“AbbVie”) on the other hand, and, solely for purposes of Section 9.1 (Mutual Representations and Warranties), Section 9.2 (Representations and Warranties of Xilio as of the Effective Date), Section 9.3 (Additional Representations and Warranties of Xilio), Section 9.4 (Additional Covenants of Xilio), Section 9.6 (Disclaimer of Warranties), Section 12.3 (Assignment) and Section 12.19 (Guarantee), Xilio Therapeutics, Inc., a Delaware corporation (“Xilio Parent”). Xilio and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION, LICENSE AND OPTION AGREEMENTCollaboration, License and Option Agreement • March 19th, 2020 • Curis Inc • Biological products, (no disgnostic substances)
This Second Amendment to Collaboration, License and Option Agreement (this “Second Amendment”) is entered into as of February 5, 2020 (the “Second Amendment Date”), by and between Aurigene Discovery Technologies Limited, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (“Aurigene”), and Curis, Inc., a corporation organized under the laws of Delaware, USA, having an address of 4 Maguire Road, Lexington, Massachusetts 02421-3112, USA (“Curis”).
ANDCollaboration, License and Option Agreement • May 15th, 2003 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIRD AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENTCollaboration, License and Option Agreement • November 14th, 2024 • Curis Inc • Biological products, (no disgnostic substances)
This Third Amendment to Collaboration, License and Option Agreement (this “Third Amendment”) is entered into as of June 4, 2020 (the “Third Amendment Date”), by and between Aurigene Discovery Technologies Limited, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (“Aurigene”), and Curis, Inc., a corporation organized under the laws of Delaware, USA, having an address of 4 Maguire Road, Lexington, Massachusetts 02421-3112, USA (“Curis”).
ContractCollaboration, License and Option Agreement • May 5th, 2020 • New York
<DOCUMENT> <TYPE>EX-10.23 <SEQUENCE>3 <FILENAME>y86403exv10w23.txt <DESCRIPTION>COLLABORATION, LICENSE AND OPTION AGREEMENT <TEXT> <PAGE> EXHIBIT 10.23 ================================================================================ COLLABORATION, LICENSE AND OPTION AGREEMENT By and Between NOVARTIS PHARMA AG, NOVARTIS PHARMACEUTICALS CORPORATION AND REGENERON PHARMACEUTICALS, INC. Dated as of March 28, 2003 ================================================================================ <PAGE> TABLE OF CONTENTS <TABLE> <CAPTION> Page ---- <S> <C> ARTICLE I DEFINITIONS............................................................................................ 2 ARTICLE II COOPERATION........................................................................................... 19 2.1 Scope of Cooperation............................................................................... 19 2.2 Compliance With Law................................................................................ 19
VIA EMAILCollaboration, License and Option Agreement • May 11th, 2020 • Acceleron Pharma Inc • Biological products, (no disgnostic substances)
Reference is hereby made to that certain Amended and Restated Collaboration, License and Option Agreement by and between Acceleron Pharma Inc. (“Acceleron”) and Celgene Corporation (“Celgene”), dated as of September 18, 2017 (the “Sotatercept Agreement”). Capitalized terms used herein that are not otherwise defined have the meanings set forth in the Sotatercept Agreement.
AMENDED AND RESTATED COLLABORATION, LICENSE AND OPTION AGREEMENT by and between ACCELERON PHARMA, INC. and CELGENE CORPORATIONCollaboration, License and Option Agreement • November 7th, 2017 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • New York
This Amended and Restated Collaboration, License and Option Agreement (this “Agreement” and, as the context requires, this “Agreement” shall mean this Agreement or the Amended Agreement) dated the 18th day of September, 2017 (the “Amended and Restated Effective Date”) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 149 Sidney Street, Cambridge, MA 02139 (“Acceleron”) and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (“Celgene”). Acceleron and Celgene may each be referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This First Amendment (“First Amendment”), dated as of March 15, 2019 (the “First Amendment Effective Date”), to the Collaboration, License and Option Agreement, dated November 6, 2018 (for purposes of this First Amendment only, the “Original Agreement”, and as amended hereby, the “Agreement”), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
eighth AMENDMENT TO Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Eighth Amendment to the Collaboration, License and Option Agreement (the “Eighth Amendment”) is entered into as of December 7, 2020 (the “Eighth Amendment Effective Date”), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
FOURTH AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENTCollaboration, License and Option Agreement • November 14th, 2024 • Curis Inc • Biological products, (no disgnostic substances)
This Fourth Amendment to Collaboration, License and Option Agreement (this “Fourth Amendment”) is entered into as of September 16, 2024 (the “Fourth Amendment Date”), by and between Aurigene Oncology Limited (formerly known as Aurigene Discovery Technologies Limited), a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (“Aurigene”), and Curis, Inc., a corporation organized under the laws of Delaware, USA, having an address of 128 Spring Street, Building C – Suite 500, Lexington, Massachusetts 02421-3112, USA (“Curis”).
Second Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Second Amendment (“Second Amendment”), dated as of August 5, 2019 (the “Second Amendment Effective Date”), to the First Amendment to Collaboration, License and Option Agreement, dated March 15, 2019 (for purposes of this Second Amendment only, the “First Amended Agreement”, and as amended hereby, the “Agreement”), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
FOURTH AMENDMENT TO Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Fourth Amendment to the Collaboration, License and Option Agreement (the “Fourth Amendment”) is entered into as of December 18, 2019 (the “Fourth Amendment Effective Date”), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
FIFTH Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Fifth Amendment to the Collaboration, License and Option Agreement (the “Fifth Amendment”) is entered into as of January 15, 2020 (the “Fifth Amendment Effective Date”) by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
SevenTH Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Seventh Amendment to the Collaboration, License and Option Agreement (the “Seventh Amendment”) is entered into as of May 14, 2020 (the “Seventh Amendment Effective Date”) by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
SIXTH Amendment to Collaboration, LICENSE and Option AgreementCollaboration, License and Option Agreement • March 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations
This Sixth Amendment to the Collaboration, License and Option Agreement (the “Sixth Amendment”) is entered into as of February 14, 2020 (the “Sixth Amendment Effective Date”) by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[* * *]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Collaboration, License and Option Agreement • August 5th, 2021 • Acceleron Pharma Inc • Biological products, (no disgnostic substances) • New York
This Collaboration, License and Option Agreement (this “Agreement”) dated the 2nd day of August, 2011 (the “Effective Date”) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 128 Sidney Street, Cambridge, MA 02139 (“Acceleron”), and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (“Celgene”). Acceleron and Celgene may each be referred to herein individually as a “Party” and collectively as the “Parties.”